Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

• Published in: Chest Vol. 154; no. 5; pp. 1061 - 1069
• Main Authors: Palmer, Scott M., Snyder, Laurie, Todd, Jamie L., Soule, Benjamin, Christian, Rose, Anstrom, Kevin, Luo, Yi, Gagnon, Robert, Rosen, Glenn
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-11-2018
• Subjects: clinical trial; idiopathic pulmonary fibrosis; lysophosphatidic acid receptor antagonist; clinical trial; lysophosphatidic acid receptor antagonist; AE; ALP; QLF; idiopathic pulmonary fibrosis; UCSD SOBQ; SF-36; qd; Dlco; SAE; LPA1; HRCT; LPA; IPF
• ISSN: 0012-3692; 1931-3543
• DOI: 10.1016/j.chest.2018.08.1058

Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF.
IM136003 was a phase 2, parallel-arm, multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-90%; diffusing capacity for carbon monoxide, 30%-80%) were randomized to receive placebo or 600 mg BMS-986020 (once daily [qd] or bid) for 26 weeks. The primary end point was rate of change in FVC from baseline to week 26.
Of 143 randomized patients, 108 completed the 26-week dosing phase. Thirty-five patients discontinued prematurely. Patient baseline characteristics were similar between treatment groups (placebo: n = 47; 600 mg qd: n = 48; 600 mg bid: n = 48). Patients treated with BMS-986020 bid experienced a significantly slower rate of decline in FVC vs placebo (−0.042 L; 95% CI, −0.106 to −0.022 vs −0.134 L; 95% CI, −0.201 to −0.068, respectively; P = .049). Dose-related elevations in hepatic enzymes were observed in both BMS-986020 treatment groups. The study was terminated early because of three cases of cholecystitis that were determined to be related to BMS-986020 after unblinding.
BMS-986020 600 mg bid treatment for 26 weeks vs placebo significantly slowed the rate of FVC decline. Both regimens of BMS-986020 were associated with elevations in hepatic enzymes.
ClinicalTrials.gov; No.: NCT01766817; URL: www.clinicaltrials.gov